Biotech Values

[DewDiligence]

Procognia Is Not a Serious Competitor for MNTA

The following post by genisi is cited in the MNTA
ReadMeFirst, but I neglected to repost it on this board.

http://siliconinvestor.advfn.com/readmsg.aspx?msgid=25180999

>>
My understanding is that Procognia's technique doesn't give a greater/better resolution of the glycan characterization than of HPLC or PEN-MALDI sequencing. Momenta's technique has a higher level of sequencing accuracy plus it can handle even smaller samples down into the picogram range.

Procognia's technique advantage is that no preparation or treatment of the sample is needed and it is quick relative to other methods. Hence, its best use is for the clone selection stage early in development of a new drug in cell lines and later for optimization and control of the manufacturing process conditions of that drug.

Teva ended its agreement with Procognia but I have no idea if it means that Teva will not take the former projects further to clinical trials. (Either way it sounds bad for Procognia).
<<

Thanks, genisi.